Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer

Cancer Gene Therapy

Volumn 13, Issue 7, 2006, Pages 658-663

  Naruishi, K ^a   Timme, T L ^a,b   Kusaka, N ^a   Fujita, T ^a   Yang, G ^a   Goltsov, A ^a   Satoh, T ^a   Ji, X ^a   Tian, W ^a   Abdelfattah, E ^a   Men, T ^a   Watanabe, M ^a   Tabata, K ^a   Thompson, T C ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Immunotherapy; Orthotopic; Prostate cancer; RTVP 1; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; GENE PRODUCT; PROTEIN P53; PROTEIN RTVP 1; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DNA MODIFICATION; EXPERIMENTAL NEOPLASM; GENE; GENETIC ANALYSIS; GENETIC TRANSDUCTION; IMMUNOSTIMULATION; IRRADIATION; ISOGRAFT; LUNG METASTASIS; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RTVP 1 GENE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; VACCINATION; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; HUMANS; MALE; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; NERVE TISSUE PROTEINS; PROSTATIC NEOPLASMS; TRANSDUCTION, GENETIC;

EID: 33747606233     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700919     Document Type: Article

References (24)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163: 1632-1642.
3. Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003; 30: 649-658.
4. Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB et al. Therapeutic targets for metastatic prostate cancer. Curr Drug Targets 2003; 4: 251-261.
5. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3: 630-641.
6. Nabel GJ. Genetic, cellular and immune approaches to disease therapy: past and future. Nat Med 2004; 10: 135-141.
7. Antonia S, Mule JJ, Weber JS. Current developments of immunotherapy in the clinic. Curr Opin Immunol 2004; 16: 130-136.
8. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
9. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK et al. Induction ofpolyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 2001; 166: 2953-2960.
10. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK et al. Demonstration ofa rational strategy for human prostate cancer gene therapy. J Urol 1994; 151: 622-628.
11. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M et al. Induction ofimmunity to prostate cancer antigens: results ofa clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 5160-5168.
12. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002; 188: 147-154.
13. Ren C, Li L, Goltsov AA, Timme TL, Tahir SA, Wang J et al. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol 2002; 22: 3345-3357.
14. Murphy EV, Zhang Y, Zhu W, Biggs J. The human glioma pathogenesis-related protein is structurally related to plant pathogenesis-related proteins and its gene is expressed specifically in brain tumors. Gene 1995; 159: 131-135.
15. Rich T, Chen P, Furman F, Huynh N, Israel MA. RTVP-1, a novel human gene with sequence similarity to genes of diverse species, is expressed in tumor cell lines ofglial but not neuronal origin. Gene 1996; 180: 125-130.
16. Gingras MC, Margolin JF. Differential expression of multiple unexpected genes during U937 cell and macrophage differentiation detected by suppressive subtractive hybridization. Exp Hematol 2000; 28: 65-76.
17. Ren C, Li L, Yang G, Timme TL, Goltsov A, Ren C et al. RTVP-1: a tumor suppressor protein inactivated by methylation in prostate cancer. Cancer Res 2004; 64: 969-976.
18. Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J et al. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 2003; 14: 91-101.
19. Shaker MR, Yang G, Timme TL, Park SH, Kadmon D, Ren C et al. Dietary 4-HPR suppresses the development ofbone metastasis in vivo in a mouse model ofprostate cancer progression. Clin Exp Metastasis 2000; 18: 429-438.
20. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L et al. Secreted Caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882-3885.
21. Satoh T, Saika T, Ebara S, Kusaka N, Timme TL, Yang G et al. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res 2003; 63: 7853-7860.
22. Saika T, Satoh T, Kusaka N, Ebara S, Mouraviev VB, Timme TL et al. Route ofadministration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther 2004; 11: 317-324.
23. Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000; 60: 1927-1933.
24. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003; 21: 2415-2432.